|
|
|
Presenting VisDRTM |
|
|
|
VisDRTM
is a pioneering
web-based service
combining
state-of-the-art imaging
technology
and a clinically
validated
assessment program
to detect, stage and
evaluate diabetic
retinopathy,
maculopathy and other
retinal diseases
resulting in an easy to
read report for primary
care physicians.
With
VisDRTM, doctors can
readily comply with
internationally endorsed
diabetic screening
guidelines in the
prevention of diabetic
complications issued by
institutions such as the
World Health
Organization ("WHO") and
International Diabetic
Federation ("IDF") in the
convenience of their own
clinics.
The method of detecting,
staging and monitoring
of diabetic related
ophthalmological
complications adopted by
VisDRTM
is the first and only
system in Asia that
achieves the United
Kingdom National
Screening Committee
standard for national
screening and reporting
("NSC"). |
|
|
|
Based on retinopathy
features,
VisDRTM
results
can: |
|
|
|
 |
Predict diabetic
retinopathy
progression |
|
|
|
|
|
|
|
Predict risk of
blindness |
|
|
|
|
|
|
Easy to
understand
“traffic
light’
scheme. All
cases graded
amber or red
should be
referred to
Ophthalmologist |
|
|
|
|
Preventive patient care
management for Diabetics
in Asia |
|
|
|
Diabetes mellitus is one
of the many chronic
health conditions that
poses a great challenge
to healthcare systems
worldwide. In Asia, it
is estimated that 113
millions people are
suffering from diabetes,
with half of them
unaware of their
illness. Diabetic
retinopathy, one of the
complications of
diabetes, is the most
common cause of
blindness among working
age individuals. While
a high proportion of
diabetes sufferers
develop diabetic
retinopathy, only a
fraction of diabetics
undergo their annual
retinal screening in
Asia.
Visual impairment is
preventable if the
condition can be
identified and treated
at an early stage of the
disease. To that end,
the World Health
Organization ("WHO") and
the International
Diabetes Federation ("IDF")
have recommended
national screening
program to monitor
retinopathy progression,
and to provide prompt
intervention as soon as
deterioration is
detected. Many
international studies
have demonstrated that
treatment such as laser
photocoagulation therapy
is effective in reducing
the rate of
proliferative disease by
as much as 60% and the
development of severe
visual loss by 90%
within a two year
period.
International clinical
guidelines such as that
developed by the
American Diabetic
Association ("ADA") and
UK NSC recommend annual retinal
examination for diabetes
patients to prevent
visual loss due to
retinopathy. VisDRTM
offers UK NSC standard eye scanning
evaluation methodology.
When combined with a
patient information
system, it can ensure
patients' adherence to
the annual retinal
screening guideline and
reduce the risk of
visual impairment.
|
|
|
|
How
VisDRTM
Operates for
Diabetic Patient Care:
|
|
|
|
We offer customer
focused services
including the
setting up and
managing of an
on-site turnkey
system for primary
healthcare
institutions such as
group medical
practices and
outpatient clinics.
VisDRTM
delivers
accurate and timely
assessment which can
significantly
improve patient care
management. For
general
practitioners and
Endocrinologists,
VisDRTM
provides easy
access from their
practice to a simple
but secured,
affordable and
clinically
validated ophthalmological
diagnostic solution. |
|
|
|
|
|
Onsite Imaging
|
|
|
|
 The
VisDRTM
turnkey service employs
a non-invasive imaging
procedure which includes
visual acuity
determination, pupil
dilatation, intraocular
pressure measurement pre
and post dilation
(optional) and 45 degree
view colour digital
retinal imaging which is
done in the convenience
of the primary care
location.
|
|
|
|
Clinically Validated Assessment
Process |
|
|
|
Experienced accredited
technicians and
ophthalmologists using a
specifically developed
software to review
colour retinal
images, determine the
diabetic retinopathy
disease scores and stage
the disease according to
the UK NSC scale which is
based on the ETDRS ("The Early
Treatment Diabetic
Retinopathy Study")
scale.
|
|
|
|
Cumulative Rate (%) of
High-risk Proliferative
Diabetic Retinopathy
("PDR") |
|
 |
|
|
| |
NSC |
Description |
|
|
R0 |
No DR.
Annual screening
|
|
|
R1 |
Background.
Annual screen,
inform doctor
|
|
|
|
R2 |
Pre-proliferative.
Refer
to Ophthalmology
|
|
| |
R3 |
Proliferative.
Fast-track refer to
Ophthalmology
|
|
|
|
|
|
VisDRTM's clinically
validated
assessment program
provides the digital
"gold standard" of
diabetic retinopathy
screening service to primary care
providers who can offer
the best care to their
patients. |
|
|
|
Reporting |
|
|
|
Report is prepared for
each case and sent to
the prescribing doctor
within 5 working days.
Each report is
color-coded depending on
the severity of the
disease and the level of
follow up action
required.
Red
report indicates advance
stage of retinopathy
requiring immediate
referral to
ophthalmologist
Amber
report indicates
moderate level of
retinopathy and patient
should be referred to
ophthalmologist soon
Green
reports indicates a
stable condition and
patient should return
for
VisDRTM
test in 12
months
Not only is the report
easy to understand, the
color codes of the
report provides a risk
priority index to alert
both physicians and
their patients. VisDRTM
enhances the chance of
identifying patients at
risk of developing
severe diabetic
retinopathy, maculopathy
and other retinal
diseases in a
reliable and easily
accessible manner both
for patients and their
care providers. |
|
|
|
Patient Follow-up |
|
|
|
Interpretation of the
report and follow-up by
the primary care doctor
completes the
VisDRTM
service cycle.
VisDRTM
report predicts the
cumulative risk of
developing into more
severe diabetic
retinopathy if untreated
and the recommendations
on the necessary action
is based on the assigned
stage of the disease on
the report.
VisDRTM
can be integrated
into any primary care
facility or secondary
care institution in
providing a
comprehensive approach
to patient care
management. |
|
|
|
|
